About Fate Therapeutics (NASDAQ:FATE)
Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.
Industry, Sector and Symbol
Trailing P/E Ratio-10.7352941176471
Forward P/E Ratio-12.03
Sales & Book Value
Annual Sales$4.11 million
Price / Sales140.59
Price / CashN/A
Book Value$1.51 per share
Price / Book7.25
Return on Equity-71.00%
Return on Assets-50.95%
Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions
What is Fate Therapeutics' stock symbol?
Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."
How were Fate Therapeutics' earnings last quarter?
Fate Therapeutics Inc (NASDAQ:FATE) issued its earnings results on Monday, March, 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.24) by $0.05. The biopharmaceutical company earned $1.03 million during the quarter, compared to analysts' expectations of $1.02 million. Fate Therapeutics had a negative net margin of 1,046.08% and a negative return on equity of 71.00%. The firm's revenue was up .0% compared to the same quarter last year. View Fate Therapeutics' Earnings History.
When will Fate Therapeutics make its next earnings announcement?
Where is Fate Therapeutics' stock going? Where will Fate Therapeutics' stock price be in 2018?
7 equities research analysts have issued 1 year target prices for Fate Therapeutics' stock. Their predictions range from $7.00 to $20.00. On average, they anticipate Fate Therapeutics' share price to reach $14.67 in the next twelve months. View Analyst Ratings for Fate Therapeutics.
What are Wall Street analysts saying about Fate Therapeutics stock?
Here are some recent quotes from research analysts about Fate Therapeutics stock:
- 1. HC Wainwright analysts commented, "Fate Announces Updated Data From Phase 1 of PROTECT; Reiterate Neutral Updated ProTmune data shows continued safety and efficacy. Yesterday, Fate Therapeutics announced additional Phase 1 clinical data from PROTECT. As a reminder, Fate is investigating ProTmune, a next-generation hematopoietic cell graft for the prevention of acute graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT). Data reported at ASH indicated that all subjects (n=7) remained relapse-free, and there were no events of graft failure or serious adverse events (SAEs) that were deemed related to ProTmune. In the study, three out of seven subjects experienced acute GvHD in the first 100 days. However, all subjects responded to standard-of care steroid treatment, and all three cases of GvHD resolved within 5-8 days." (3/20/2018)
- 2. According to Zacks Investment Research, "Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California. " (3/7/2018)
Are investors shorting Fate Therapeutics?
Fate Therapeutics saw a increase in short interest during the month of February. As of February 28th, there was short interest totalling 2,301,328 shares, an increase of 28.7% from the February 15th total of 1,787,969 shares. Based on an average daily trading volume, of 1,043,005 shares, the days-to-cover ratio is currently 2.2 days. Currently, 12.1% of the company's shares are short sold.
Who are some of Fate Therapeutics' key competitors?
Some companies that are related to Fate Therapeutics include Cellectis (CLLS), Assembly Biosciences (ASMB), Genomic Health (GHDX), Acorda Therapeutics (ACOR), Revance Therapeutics (RVNC), Wave Life Sciences (WVE), ARMO BioSciences (ARMO), Audentes Therapeutics (BOLD), Myovant Sciences (MYOV), TherapeuticsMD (TXMD), DBV Technologies (DBVT), Dynavax Technologies (DVAX), Athenex (ATNX), Bavarian Nordic (BVNRY), Zai Lab (ZLAB), Biohaven Pharmaceutical (BHVN), Intellia Therapeutics (NTLA) and Adaptimmune Therapeutics (ADAP).
Who are Fate Therapeutics' key executives?
Fate Therapeutics' management team includes the folowing people:
- William H. Rastetter Ph.D., Independent Chairman of the Board (Age 68)
- J. Scott Wolchko, President, Chief Executive Officer, Principal Executive Officer, Director (Age 44)
- John D. Mendlein Ph.D., Vice Chairman of the Board (Age 57)
- Jim Beitel, Senior Vice President - Corporate Development
- Daniel D. Shoemaker Ph.D., Chief Scientific Officer (Age 47)
- John Ferraro, Vice President - Clinical Operations
- Wendy Levin, Vice President - Clinical Development
- Walter Grubb, Vice President - Business Development
- Cindy Tahl J.D., General Counsel
- Stewart Abbot Ph.D., Chief Development Officer
Has Fate Therapeutics been receiving favorable news coverage?
Media stories about FATE stock have trended somewhat positive on Thursday, Accern reports. The research firm ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Fate Therapeutics earned a news sentiment score of 0.08 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 45.45 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are Fate Therapeutics' major shareholders?
Fate Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (11.84%), Redmile Group LLC (10.72%), BlackRock Inc. (3.35%), 683 Capital Management LLC (1.67%), Endurant Capital Management LP (1.09%) and Geode Capital Management LLC (0.68%). Company insiders that own Fate Therapeutics stock include Chris Storgard, Cindy Tahl, Daniel D Shoemaker and William H Rastetter. View Institutional Ownership Trends for Fate Therapeutics.
Which major investors are selling Fate Therapeutics stock?
FATE stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Renaissance Technologies LLC, Franklin Resources Inc. and Rhumbline Advisers. Company insiders that have sold Fate Therapeutics company stock in the last year include Cindy Tahl and Daniel D Shoemaker. View Insider Buying and Selling for Fate Therapeutics.
Which major investors are buying Fate Therapeutics stock?
FATE stock was purchased by a variety of institutional investors in the last quarter, including Redmile Group LLC, Millennium Management LLC, Monashee Investment Management LLC, Endurant Capital Management LP, Victory Capital Management Inc., J. Goldman & Co LP, 683 Capital Management LLC and Two Sigma Investments LP. Company insiders that have bought Fate Therapeutics stock in the last two years include Chris Storgard and William H Rastetter. View Insider Buying and Selling for Fate Therapeutics.
How do I buy shares of Fate Therapeutics?
Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fate Therapeutics' stock price today?
One share of FATE stock can currently be purchased for approximately $10.95.
How big of a company is Fate Therapeutics?
Fate Therapeutics has a market capitalization of $604.24 million and generates $4.11 million in revenue each year. The biopharmaceutical company earns $-42,950,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Fate Therapeutics employs 80 workers across the globe.
How can I contact Fate Therapeutics?
Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]
MarketBeat Community Rating for Fate Therapeutics (FATE)MarketBeat's community ratings are surveys of what our community members think about Fate Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Fate Therapeutics (NASDAQ:FATE) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||3.00||3.00||3.00||3.00|
|Ratings Breakdown: ||0 Sell Rating(s)|
1 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$14.67||$7.67||$7.67||$7.00|
|Price Target Upside: ||33.94% upside||10.15% upside||82.54% upside||67.06% upside|
Fate Therapeutics (NASDAQ:FATE) Consensus Price Target History
Fate Therapeutics (NASDAQ:FATE) Analyst Ratings History
(Data available from 3/22/2016 forward)
Fate Therapeutics (NASDAQ:FATE) Earnings History and Estimates Chart
Fate Therapeutics (NASDAQ FATE) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/5/2018||Q4 2017||($0.24)||($0.29)||$1.02 million||$1.03 million||View||Listen|
|11/1/2017||Q3 2017||($0.25)||($0.26)||$0.95 million||$1.03 million||View||N/A|
|8/14/2017||Q2 2017||($0.24)||($0.23)||$1.02 million||$1.03 million||View||N/A|
|5/15/2017||Q1 2017||($0.21)||($0.24)||$1.04 million||$1.03 million||View||N/A|
|3/16/2017||Q4 2016||($0.28)||($0.21)||$1.06 million||$1.03 million||View||N/A|
|11/7/2016||Q316||($0.29)||($0.27)||$1.05 million||$1.03 million||View||Listen|
|8/8/2016||Q216||($0.32)||($0.29)||$1.02 million||$1.03 million||View||N/A|
|5/9/2016||Q116||($0.25)||($0.29)||$0.84 million||$1.32 million||View||N/A|
|3/3/2016||Q415||($0.27)||($0.26)||$0.58 million||$1.08 million||View||N/A|
|11/3/2015||Q315||($0.32)||($0.24)||$0.46 million||$1.03 million||View||N/A|
|8/5/2015||Q215||($0.39)||($0.33)||$0.31 million||$0.33 million||View||N/A|
Fate Therapeutics (NASDAQ:FATE) Earnings Estimates
2018 EPS Consensus Estimate: ($0.88)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Fate Therapeutics (NASDAQ:FATE)
No dividend announcements for this company have been tracked by MarketBeat.com
Fate Therapeutics (NASDAQ FATE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 10.88%
Institutional Ownership Percentage: 66.43%
Fate Therapeutics (NASDAQ FATE) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|10/16/2017||Cindy Tahl||General Counsel||Sell||8,091||$3.85||$31,150.35|| |
|10/16/2017||Daniel D Shoemaker||Insider||Sell||13,225||$3.87||$51,180.75|| |
|11/23/2016||Chris Storgard||Insider||Buy||37,593||$2.66||$99,997.38||9,090|| |
|11/23/2016||William H Rastetter||Director||Buy||375,939||$2.66||$999,997.74|| |
|6/12/2014||Peter D Flynn||Insider||Sell||6,488||$7.00||$45,416.00|| |
|6/10/2014||Peter D Flynn||Insider||Sell||3,305||$7.00||$23,135.00|| |
|5/1/2014||Peter D Flynn||Insider||Sell||9,793||$7.07||$69,236.51|| |
|4/4/2014||Peter D Flynn||Insider||Sell||5,889||$8.00||$47,112.00|| |
|4/2/2014||Christian Weyer||Insider||Sell||10,000||$9.02||$90,200.00|| |
|4/1/2014||J Scott Wolchko||Insider||Sell||20,000||$9.64||$192,800.00|| |
|3/31/2014||Daniel D Shoemaker||CTO||Sell||8,653||$9.86||$85,318.58|| |
|10/4/2013||John Mendlein||Director||Buy||16,667||$6.00||$100,002.00|| |
|10/4/2013||Venture Fund Vi Lp Arch||Major Shareholder||Buy||833,333||$6.00||$4,999,998.00|| |
Fate Therapeutics (NASDAQ FATE) News Headlines
Fate Therapeutics (NASDAQ:FATE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Fate Therapeutics (NASDAQ:FATE) Income Statement, Balance Sheet and Cash Flow Statement
Fate Therapeutics (NASDAQ FATE) Stock Chart for Thursday, March, 22, 2018